

## References

- Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016). Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA*, 315(4), 371–379.
- Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., & Liechti, M. E. (2022). Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects. *Clinical Pharmacology & Therapeutics*, 111(4), 886–895.
- Bonson, K. R., & Murphy, D. L. (1995). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. *Behavioural Brain Research*, 73(1–2), 229–233.
- Bonson, K. (1996). Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans. *Neuropsychopharmacology*, 14(6), 425–436.
- Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015). LSD enhances suggestibility in healthy volunteers. *Psychopharmacology*, 232(4), 785–794.
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine*, 384(15), 1402–1411.
- Cohen, S. (1967). Psychotherapy with LSD: Pro and con. In H. A. Abramson (Ed.), *The use of LSD in psychotherapy and alcoholism*. The Bobbs-Merrill Company.
- Colombo, C., Benedetti, F., Barbini, B., Campori, E., & Smeraldi, E. (1999). Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. *Psychiatry research*, 86(3), 267-270.
- Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*.
- Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T., & Griffiths, R. R. (2021). Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. *Journal of Psychopharmacology*.
- Donohue, A. (2010). First manic episode in a 55-year-old man after initiation of aripiprazole. *Psychiatry (Edgmont)*, 7(4), 37.
- Fiore, M. C., Smith, S. S., Jorenby, D. E., & Baker, T. B. (1994). The Effectiveness of the Nicotine Patch for Smoking Cessation: A Meta-analysis. *JAMA*, 271(24), 1940–1947.

- Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *Journal of Nervous and Mental Disease*, 202(7), 513–520.
- Goldberg, J. F., & Truman, C. J. (2003). Antidepressant-induced mania: an overview of current controversies. *Bipolar disorders*, 5(6), 407-420.
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Bruschi, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., ... Rademaker, M. C. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *N Engl J Med*, 12.
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology*, 30(12), 1181–1197.
- Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Archives of General Psychiatry*, 68, 71–78.
- Grof, S., & Dytrych, Z. (1965). Blocking of LSD reaction by premedication with Niamid. *Activitas Nervosa Superior*, 7(3), 306.
- Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (1973). LSD-Assisted Psychotherapy in Patients with Terminal Cancer. *International Pharmacopsychiatry*, 8(3), 129–144.
- Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *Journal of Psychopharmacology*, 36(2), 151–158.
- Jones, B. D., Razza, L. B., Weissman, C. R., Karbi, J., Vine, T., Mulsant, L. S., ... & Daskalakis, Z. J. (2021). Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. *JAMA Network Open*, 4(9), e2125531-e2125531.
- Kast, E. C., & Collins, V. J. (1964). Study of Lysergic Acid Diethylamide As an Analgesic Agent. *Anesthesia and Analgesia*, 43(February), 285–291.
- Kast, E. (1966). LSD and the Dying Patient. *Chicago Medical School Quarterly*, 26(2), 80–87.
- Kast, E. (1967). Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. *The Psychiatric Quarterly*, 41(4), 646–657.

- Keating, A. M., Aoun, S. L., & Dean, C. E. (2005). Ziprasidone-associated mania: a review and report of 2 additional cases. *Clinical neuropharmacology*, 28(2), 83-86
- Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022). The neural basis of psychedelic action. *Nature Neuroscience*, 25(11), 1407–1419.
- Lee, J., Arcand, L., Narang, P., & Lippmann, S. (2014). ECT-induced mania. *Innovations in Clinical Neuroscience*, 11(11-12), 27.
- Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., ... Lewis, G. (2021). Maintenance or Discontinuation of Antidepressants in Primary Care. *New England Journal of Medicine*, 385(14), 1257–1267.
- Luborsky, L., Rosenthal, R., Diguier, L., Andrusyna, T. P., Berman, J. S., Levitt, J. T., Seligman, D. A., & Krause, E. D. (2002). The Dodo bird verdict is alive and well—Mostly. *Clinical Psychology: Science and Practice*, 9(1), 2–12.
- Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. *Cell Reports*, 23(11), 3170–3182.
- Madsen, M. K., Fisher, P. M. D., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT<sub>2A</sub> receptor binding. *European Neuropsychopharmacology*, 33, 71–80.
- Middlefell, R. (1967). The effects of LSD on body sway suggestibility in a group of hospital patients. *British Journal of Psychiatry*, 113(496), 277–280.
- Nayak, S. M., & Johnson, M. W. (2020). Psychedelics and psychotherapy. *Pharmacopsychiatry*.
- Nayak, S. M., Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzoe, D., Nutt, D. J., & Carhart-Harris, R. (2022). A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression. *Psychedelic Medicine*, psymed.2022.0002.
- Olson, D. E. (2020). The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. *ACS Pharmacology & Translational Science*, 4(2), 563-567.
- Pahnke, W., Kurland, A., Goodman, L., & Richards, W. (1969). LSD-Assisted Psychotherapy with Terminal Cancer Patients. *Current Psychiatric Therapies*, 9, 144–152.
- Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L.,

- Lobão-Soares, B., ... Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. *Psychological Medicine*, 49(4), 655–663.
- Paszek, A. (2017). A Meta-Analysis of the Efficacy of Bupropion Sustained-Release for Smoking Cessation in Heavy Smokers. *Impulse*, 11.
- Patel, R., Reiss, P., Shetty, H., Broadbent, M., Stewart, R., McGuire, P., & Taylor, M. (2015). Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. *BMJ open*, 5(12), e008341.
- Richards, W., Rhead, J., DiLeo, Francesco, Yensen, R., & Kurland, A. (1977). The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients. *Journal of Psychedelic Drugs*, 9, 1–10.
- Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009). Meta-analysis of the placebo response in antidepressant trials. *Journal of affective disorders*, 118(1-3), 1-8.
- Rosenzweig, S. (1936). Some implicit common factors in diverse methods of psychotherapy. *American Journal of Orthopsychiatry*, 6(3), 412–415.
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzis, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. *Journal of Psychopharmacology*, 30(12), 1165–1180.
- Rotz, R. von, Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. *EClinicalMedicine*, 56.
- Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. *Neuron*, 109(16), 2535-2544.e4.
- Sit, D. K., McGowan, J., Wiltrout, C., Diler, R. S., Dills, J., Luther, J., ... & Wisner, K. L. (2018). Adjunctive bright light therapy for bipolar depression: a randomized double-blind placebo-controlled trial. *American Journal of Psychiatry*, 175(2), 131-139.
- Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016). Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities. *Psychopharmacology*, 233(5), 823–829.
- Traber, R., Schneiter, R., & Modestin, J. (2007). A case of aripiprazole-induced mania. *Pharmacopsychiatry*, 40(01), 37-38.

Wallace, A. F. C. (1959). Cultural Determinants of Response to Hallucinatory Experience. *Archives of General Psychiatry*, 1(1), 58.

Wehr, T. A., & Sack, D. A. (1987). Sleep disruption: A treatment for depression and a cause of mania. *Psychiatric Annals*, 17(10), 654-663.

Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020). Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. *Frontiers in Psychiatry*, 11, 5.

Yaden, D. B., & Griffiths, R. R. (2021). The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. *ACS Pharmacology and Translational Science*, 4(2), 568–572.